KP802

FP802 is an orally active potent TwinF interface inhibitor that disrupts and detoxifies the NMDAR/TRPM4 death complex. FP802 exerts powerful neuroprotective effects in the 5xFAD mouse model of Alzheimer’s disease (AD) by preventing cognitive decline, preserving neuronal structural integrity, reducing amyloid-β plaque formation, and mitigating mitochondrial pathology[1]. FP802 stops loss of motor neurons, reduces serum neurofilament light chain (NfL) levels, improves motor performance, and extends life in a mouse model of amyotrophic lateral sclerosis (ALS) [2]. FP802 can be used for AD and ALS research[1][2].

61694-81-3

12352005

H302-H314-H335

IGluR; TRP Channel

Membrane Transporter/Ion Channel; Neuronal Signaling

Neuroscience-Neurodegeneration

Neurological Disease

CCN(CC1=CC(Cl)=CC=C1)CCN

C11H17ClN2

212.72

P260-P264-P270-P271-P280-P301+P330+P331-P303+P361+P353-P304+P340-P305+P351+P338-P363-P403+P233-P405-P501

[1]Yan J, et al. The NMDAR/TRPM4 death complex is a major promoter of disease progression in the 5xFAD mouse model of Alzheimer's disease. Mol Psychiatry. 2025 Aug 26.|[2]Yan J, et al. TwinF interface inhibitor FP802 stops loss of motor neurons and mitigates disease progression in a mouse model of ALS. Cell Rep Med. 2024 Feb 20;5 (2) :101413.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W611371/

Reference compound1

No Development Reported